<p>Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib</p>
Hongge Liang(Guangdong University of Technology), Mengzhao Wang(Peking Union Medical College Hospital), Di Ma(Chinese Academy of Medical Sciences & Peking Union Medical College), Yan Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Junling Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaoyan Liu(Xinjiang Agricultural University), Jing Zhao(Chinese Academy of Medical Sciences & Peking Union Medical College), Wei Zhong(Chinese Academy of Medical Sciences & Peking Union Medical College), Minjiang Chen(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 6
Related Papers
Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19)
|Clinical Infectious Diseases|2020|556
Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study
|The Lancet Regional Health - Western Pacific|2023|112
<p>MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis</p>
|OncoTargets and Therapy|2020|111
Blocking the formation of radiation-induced breast cancer stem cells
|Oncotarget|2014|109